METIS TECHBIO-P (07666) jumped nearly 8% during intraday trading, pushing its cumulative monthly gains past the 30% mark. As of the time of writing, the stock had risen 6.29% to HK$13.01, with a turnover of HK$31.8484 million.

Shenwan Hongyuan released a research report stating that METIS TECHBIO-P's AI4S platform, centered on nanomaterials and drug delivery, is essentially a high-barrier, forward-looking "future technology." Its valuation logic should not be limited to historical targets with identical business models, but should instead reference high-growth sectors with similar technological attributes that are currently favored by the market.

CITIC Construction Securities noted that as the NanoForge and AI platforms continue to expand external collaborations, the dual-driver model is increasingly validated. The firm is optimistic about METIS TECHBIO-P's long-term value in the AI-driven small molecule drug formulation development sector.